Diasorin (OTCMKTS:DSRLF) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “

Diasorin (DSRLF) remained flat at $$90.94 during midday trading on Tuesday. Diasorin has a fifty-two week low of $54.86 and a fifty-two week high of $93.25.

ILLEGAL ACTIVITY NOTICE: “Diasorin (DSRLF) Lowered to Hold at Zacks Investment Research” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/diasorin-dsrlf-lowered-to-hold-at-zacks-investment-research.html.

Diasorin Company Profile

DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; gastrointestinal infections; autoimmunity; and cardiac and brain damages.

Get a free copy of the Zacks research report on Diasorin (DSRLF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Diasorin Spa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diasorin Spa and related companies with MarketBeat.com's FREE daily email newsletter.